Economic Atlas
Companies/Lixte Biotechnology Holdings, Inc.
Company profile

Lixte Biotechnology Holdings, Inc.

NASDAQ: LIXT · Healthcare · Biotechnology
PublicHQ Pasadena, CA · Los AngelesCIK 0001335105Reports USD
#1001 of 1,418 Healthcare companies by revenue
EA Score
40D
Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$6.1M
Employees
3
as of 2026-08-18
Market cap
$89.1M
as of 2026-08-18

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$200.0k$200.0k2015
Net income-$6.1M-$6.1M2025
Operating income-$5.1M-$5.1M2025
Total assets$12.7M$12.7M2025
Liabilities$1.8M$1.8M2025
Equity$9.7M$9.7M2025

Revenue trend

FY2011 – FY2015 · USD
FY11
FY11
FY12
FY13
FY15

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Lixte Biotechnology Holdings, Inc.’s revenue?

Lixte Biotechnology Holdings, Inc. booked $200.0k in FY2015 revenue — among the slowest-growing Healthcare companies we track, at a -3039.3% net margin.

Peers · Healthcare
Anixa Biosciences, Inc.52DGlucoTrack, Inc.28DSharps Technology, Inc.33DClene Inc.27DWindtree Therapeutics, Inc.——CardioComm Solutions, Inc.25D
Neighbors
Los Angeles →
The Walt Disney Company$94.4B72BPublic Storage$4.8B80B+Southern California Gas Company PFD SER A 6%——Ares Management Corporation$5.6B68BLive Nation Entertainment, Inc.$25.2B76B+Rocket Lab USA, Inc.$601.8M50D
Key facts
CEOGeordan G. Pursglove
SectorHealthcare
IndustryBiotechnology
HeadquartersPasadena, CA
ExchangeNASDAQ: LIXT
Employees3
IPO date2007-10-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.